Fate Therapeutics (FATE) Assets (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Assets came in at $284.9 million in Q1 2026, down 28.53% YoY from $398.7 million in Q1 2025, and down 10.67% on a QoQ basis from $318.9 million in Q4 2025.
Fate Therapeutics (FATE) Assets (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Assets data on file, last reported at $284.9 million in Q1 2026.
- Quarterly Assets fell 28.53% year-over-year to $284.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.9 million (down 28.53% YoY) and the FY2025 annual result came in at $318.9 million, down 27.63% from the prior year.
- Assets eased to $284.9 million in Q1 2026, from $318.9 million in the prior quarter.
- In the past five years, Assets ranged from a high of $858.4 million in Q1 2022 to a low of $284.9 million in Q1 2026.
- A 5-year average of $537.5 million and a median of $528.8 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets dropped 8.98% — and 2025, when it tumbled 30.57%.
- Tracing FATE's Assets over 5 years: stood at $705.6 million in 2022, then declined by 28.25% to $506.2 million in 2023, then declined by 12.94% to $440.7 million in 2024, then decreased by 27.63% to $318.9 million in 2025, then declined by 10.67% to $284.9 million in 2026.
- The last three Assets figures came in at $284.9 million (Q1 2026), $318.9 million (Q4 2025), and $343.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 284.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 284.92 Mn |
| Dec 31, 2025 | 318.94 Mn |
| Sep 30, 2025 | 343.67 Mn |
| Jun 30, 2025 | 371.63 Mn |
| Mar 31, 2025 | 398.67 Mn |
| Dec 31, 2024 | 440.69 Mn |
| Sep 30, 2024 | 494.97 Mn |
| Jun 30, 2024 | 528.82 Mn |
| Mar 31, 2024 | 569.89 Mn |
| Dec 31, 2023 | 506.22 Mn |
| Sep 30, 2023 | 543.79 Mn |
| Jun 30, 2023 | 584.76 Mn |
| Mar 31, 2023 | 630.34 Mn |
| Dec 31, 2022 | 705.56 Mn |
| Sep 30, 2022 | 749.35 Mn |
| Jun 30, 2022 | 807.06 Mn |
| Mar 31, 2022 | 858.39 Mn |
| Dec 31, 2021 | 921.46 Mn |
| Sep 30, 2021 | 984.57 Mn |
| Jun 30, 2021 | 1.02 Bn |